INT320644

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 5.90
Pain Relevance 0.56

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (Egfr) cell morphogenesis (Egfr) intracellular (Egfr)
enzyme binding (Egfr) cytoplasm (Egfr) signal transducer activity (Egfr)
Anatomy Link Frequency
skin 1
parenchyma 1
Egfr (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Potency 12 94.56 High High
Inflammation 42 87.56 High High
Pain 12 87.04 High High
alcohol 6 85.68 High High
ischemia 5 81.48 Quite High
Intracerebroventricular 1 76.56 Quite High
pruritus 12 57.24 Quite High
pregabalin 6 56.40 Quite High
Antihistamine 18 5.00 Very Low Very Low Very Low
corticosteroid 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Exanthema 210 99.98 Very High Very High Very High
Paronychia 30 99.98 Very High Very High Very High
Infection 18 99.50 Very High Very High Very High
Candida Infection 6 99.28 Very High Very High Very High
Acne 24 97.50 Very High Very High Very High
Cancer 54 96.12 Very High Very High Very High
Pyogenic Granuloma 6 94.88 High High
Abscess 6 93.96 High High
Toxicity 150 93.92 High High
INFLAMMATION 42 87.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The STEPP trial evaluated the differences between pre-emptive and reactive treatments for skin toxicities associated with EGFR inhibition by panitumumab in 58 patients receiving panitumumab plus FOLFIRI or irinotecan-only chemotherapy for second-line treatment of mCRC54.
EGFR Binding (associated) of in skin
1) Confidence 0.34 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 0.48 Pain Relevance 0
Secondary bacterial (S. aureus) or fungal (Candida albicans) infection is common in paronychia associated with EGFR inhibition29,63,64.
EGFR Binding (associated) of associated with paronychia, infection and candida infection
2) Confidence 0.34 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 1.19 Pain Relevance 0.38
Canadian guidelines have recently been developed for the prevention and management of dermatological toxicities associated with anti-EGFR MoAb treatment52.
anti-EGFR Binding (associated) of
3) Confidence 0.34 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 1.06 Pain Relevance 0.04
Binding of these ligands results in EGFR dimerization, which leads to high-affinity ligand binding, activation of the intrinsic protein tyrosine kinase (TK) activity, and tyrosine autophosphorylation.
EGFR Binding (dimerization) of
4) Confidence 0.34 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 0.12 Pain Relevance 0
These results suggest that the characteristic rash associated with EGFR inhibitors may have potential as a surrogate marker of efficacy in patients with KRAS wild type tumors.


EGFR Binding (associated) of associated with exanthema and cancer
5) Confidence 0.34 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 1.11 Pain Relevance 0.03
Therefore, terms that imply a similarity with acne, such as “acneiform rash”, “acneiform follicular rash”, “acne-like rash”, “maculopapular rash”, or “monomorphic pustular lesions”, should not be used to describe the papulopustular rash associated with anti-EGFR therapy36,37,43,44.
anti-EGFR Binding (associated) of associated with exanthema and acne
6) Confidence 0.34 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 1.72 Pain Relevance 0
As a result of the BBB disruption, fibrinogen is shown to enter the brain parenchyma, where it binds and induces the phosphorylation of epidermal growth factor receptor (EGFR) in an integrin- and src-dependent manner [45].
EGFR Binding (binds) of in parenchyma
7) Confidence 0.14 Published 2010 Journal BMC Neurol Section Body Doc Link PMC3020671 Disease Relevance 0.21 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox